Maximus Tribe Review 2026: Enclomiphene + Pregnenolone, Fertility Preservation, and the 2x T Claim

Last updated: May 20, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~9 min read

How Maximus Tribe is different from every other TRT clinic

Most online TRT clinics — Hone Health, Defy Medical, Marek Health, Henry Meds — start patients on exogenous testosterone (cypionate injection, cream, or troche). That works fast and reliably raises serum testosterone, but it has two trade-offs: it suppresses your own LH and FSH production via negative feedback at the pituitary, which shuts down endogenous testosterone synthesis and impairs spermatogenesis (often dramatically). For men over 40 who are done having kids, that’s acceptable. For men under 40, it’s often a deal-breaker.

Maximus Tribe, founded in 2021, built its entire positioning around the alternative: drugs that stimulate the hypothalamic-pituitary-testicular (HPT) axis to produce more of your own testosterone. The mechanism is fundamentally different from replacement, and the fertility implications are the opposite.

For a shorter brand snapshot, see our original Maximus Tribe brand review. This 2026 piece focuses on the mechanism, the price math, the 2x T data claim, and where Maximus is the wrong choice.

[provider=”maximus-tribe”]

The enclomiphene + pregnenolone protocol explained

Maximus’s flagship product is a daily dissolvable tablet containing enclomiphene citrate and pregnenolone. Here is how each component works, and why the combination matters.

Enclomiphene — a selective estrogen receptor modulator (SERM)

Enclomiphene is the trans-isomer of clomiphene citrate. It blocks estrogen receptors at the hypothalamus, which the hypothalamus interprets as “estrogen is low.” In response, the hypothalamus increases GnRH pulse frequency, which drives the pituitary to release more LH and FSH, which drives the testes to produce more testosterone (LH effect) and more sperm (FSH effect).

Net result: total testosterone rises, often substantially, without suppressing the HPT axis. Spermatogenesis is preserved or improved. Testicular size is preserved. This is the opposite of what exogenous testosterone does.

Enclomiphene is well-supported in the peer-reviewed literature for secondary hypogonadism — Wiehle et al. (2014) demonstrated significant total testosterone increases while preserving sperm parameters; subsequent studies have replicated the finding. It is not FDA-approved as a standalone product for hypogonadism (clomiphene is the closest approved analog, also off-label), so enclomiphene is prescribed off-label and dispensed by compounding pharmacies.

Pregnenolone — the upstream steroid precursor

Pregnenolone is the precursor steroid from which the body synthesizes most other steroid hormones — DHEA, progesterone, cortisol, and testosterone. The Maximus rationale is that supplementing pregnenolone provides additional substrate for the now-stimulated testes to convert into testosterone, supporting the enclomiphene mechanism. The evidence base for pregnenolone supplementation specifically increasing testosterone is thinner than the enclomiphene evidence, and writers should not overstate it.

2026 pricing: monthly vs annual plans + lab costs

Maximus has two main plan structures and an entry promo as of May 2026:

All-in year-1 cost on the annual plan: roughly $1,585. On the monthly plan: roughly $2,533. That positions Maximus very competitively against Hone Health’s ~$1,900–$2,300/yr — slightly cheaper on the annual plan, similar on the monthly plan, and meaningfully cheaper than concierge options like Defy or Marek.

The two upfront lab draws are non-negotiable. Maximus requires confirmation of low total testosterone before prescribing, consistent with AUA 2024 and Endocrine Society guidance. Skipping labs is not on the table.

Maximus traditional TRT track (for men who fail enclomiphene)

Enclomiphene does not work for everyone. Men with primary hypogonadism — where the testes themselves have failed (Klinefelter, post-chemotherapy, testicular trauma, congenital anorchia) — cannot respond to enclomiphene because the LH signal has nowhere to act. For these patients, exogenous testosterone replacement is the only option.

Maximus added a traditional TRT track (testosterone cream and injection) in 2023 to serve men who either present with primary hypogonadism or who tried enclomiphene for 12+ weeks without adequate response. The traditional track uses the same intake and lab process; pricing is broadly comparable to the enclomiphene tier.

For the broader comparison between replacement and stimulation, see Hone vs Maximus 2026.

The 2x testosterone data claim — does the science hold?

Maximus markets a “~2x total testosterone increase” figure based on its internal patient data. The mechanism (enclomiphene) is well-supported in the peer-reviewed literature, and a roughly 1.8–2.5x rise in total testosterone over 8–12 weeks is broadly consistent with published enclomiphene studies. Wiehle et al. (2014, J Sex Med) reported total testosterone increases in this range in hypogonadal men treated with enclomiphene 12.5 mg or 25 mg daily.

That said, two caveats apply to any sponsored data figure:

• Selection effect: Maximus patients who report data are unlikely to be a random sample of all patients.
• Baseline anchoring: A “2x” increase from a low baseline (e.g., 220 ng/dL → 440 ng/dL) is clinically meaningful but still in the lower-mid reference range. Marketing language should not be confused with a guarantee of supraphysiologic optimization.

Bottom line: the mechanism is real, the magnitude is plausible, but treat the headline number as an order-of-magnitude expectation, not a contractual promise.

[provider=”maximus-tribe”]

Fertility preservation: why this matters for under-40 men

Exogenous testosterone suppresses LH and FSH within weeks of starting therapy. Reduced FSH means reduced spermatogenesis, and reduced LH means reduced intratesticular testosterone — which is the actual driver of sperm production. Many men on standard cypionate TRT see sperm counts drop to near-zero within 3–6 months. Recovery after stopping TRT is variable; some men recover fertility within months, others take 12–18 months, a small subset never fully recover.

Enclomiphene does the opposite. Because it works by increasing LH and FSH, intratesticular testosterone rises, spermatogenesis is preserved or improved, and testicular volume is maintained. For a 32-year-old man who is symptomatically hypogonadal but planning kids in the next five years, that mechanism difference is the single most important variable in the choice.

Men who want fertility preservation should also discuss hCG (human chorionic gonadotropin) with their clinician — it mimics LH directly and is often added to traditional TRT protocols at concierge clinics like Defy Medical for exactly this reason. Maximus does not currently prescribe hCG; enclomiphene is its single fertility-preservation lever.

Maximus Tribe intake & lab process

Intake takes about 10–18 days from sign-up to first dose:

1. Sign up online and complete a symptom and medical history questionnaire.
2. Receive a lab requisition; complete two morning blood draws at Quest or LabCorp (both partners supported in 2026).
3. Telehealth consult with a Maximus-affiliated clinician reviews labs, symptoms, and fertility goals.
4. If enclomiphene is appropriate, the dissolvable tablet ships from the compounding pharmacy partner.
5. Re-test at month 3 and month 6 to confirm response; dose may be titrated.

Maximus is 50-state-licensed and operates within the DEA Fourth Temporary Extension framework for 2026 — see our online testosterone prescription explainer for the legal context.

Trustpilot, refund policy, and 90-day guarantee

Maximus’s Trustpilot average sits around 4.5/5 as of May 2026 — higher than Hone’s 4.0/5, partly because the customer base self-selects for men committed to the fertility-preservation mechanism rather than price-shoppers.

The 90-day money-back guarantee is unusual in the DTC TRT space. If labs at month 3 do not show a clinically meaningful total testosterone increase, Maximus refunds the program. That guarantee is one of the strongest signals that the internal data supports the marketing claim — a clinic with poor response rates couldn’t afford to offer it.

Where Maximus falls short

• No women’s HRT. Maximus is men-only. For a partner who needs hormone care, see Hone Health (DTC) or Defy Medical (concierge).
• No peptide formulary. No BPC-157, no GHK-Cu, no growth hormone secretagogues. Marek Health and Defy Medical handle peptides.
• Wrong fit for primary hypogonadism. If your LH is already elevated and your testes have failed, enclomiphene cannot work. You need traditional TRT, which Maximus does offer as a secondary track but is not its strength.
• Limited dose personalization vs concierge. Defy Medical’s physician-led model handles complex multi-modal protocols (cypionate + hCG + anastrozole + thyroid) more flexibly than Maximus’s templated enclomiphene-first approach.

Maximus vs Hone for testosterone optimization

Who should and shouldn’t try Maximus Tribe

Maximus is the right choice if: you’re under 40 and want kids; you have secondary hypogonadism with intact testes; you want to avoid testicular atrophy; you’re nervous about lifelong exogenous testosterone; you want the 90-day guarantee safety net.

Maximus is the wrong choice if: you have primary hypogonadism (failed testes); you’re over 50 and done with fertility decisions; you want peptides or women’s HRT under the same membership; you need rapid symptom relief and can’t wait 8 weeks for enclomiphene to take effect.

Frequently asked questions

Related reading on BestMedsHub

• Testosterone telehealth hub
• Our original Maximus Tribe brand review
• Hone vs Maximus 2026 — replacement vs stimulation
• Best online TRT clinics for 2026
• TRT cost in 2026
• Online testosterone prescription 2026 — legality explainer

Sources

• Maximus Tribe pricing and protocol pages, verified May 2026.
• Maximus Tribe Trustpilot profile, accessed May 2026.
• Wiehle RD et al. Enclomiphene citrate stimulates testosterone production while preserving oligospermia: a randomized phase II clinical trial. J Sex Med, 2014.
• Kaminetsky J et al. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men. BJU Int, 2013.
• American Urological Association. Testosterone Deficiency Guideline — 2024 Amendment.
• Bhasin S. et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2018 (current).
• U.S. DEA. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities, December 19, 2025.